iKang Healthcare Group (KANG) approached by Yunfeng Capital and Alibaba

  • March 12, 2018

POTENTIAL DEAL DETAILS

StockiKang Healthcare Group, Inc.SymbolKANG
Date Announced03/12/2018Source Press release
TypeNews Report
Date of Confirmation: 03/26/2018Price at Confirmation: $19.95
Potential Profit: 6.12%Annualized Profit: 159.48%

iKang Healthcare Group, Inc. (KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced certain developments with respect to the previously disclosed potential going private transaction proposed by Yunfeng Capital. The Special Committee has received a proposal from Yunfeng and Alibaba Investment Limited (“Alibaba”), proposing a transaction in which a consortium led by Yunfeng and Alibaba would acquire all of the outstanding shares.

Update(s):

March 26, 2018: iKang Healthcare Group, Inc. (KANG), a major provider in China’s fast growing private preventive healthcare services market, today announced that it has entered into a definitive Agreement and Plan of Merger with IK Healthcare Investment Limited , a special purpose vehicle wholly-owned by one or more affiliates of Yunfeng Capital and Alibaba Group Holding Limited ,  and IK Healthcare Merger Limited, a wholly-owned subsidiary of Parent.

 

Disclaimer: Our intent with this section of the website is to present potential deals that appear to be in the pipeline. These potential deals are ones where i) the company has indicated that it is "seeking strategic alternatives", ii) there has been an unsolicited bid for a company as mentioned in a press release by the company or iii) news about the deal has been published by a leading news organization like The Wall Street Journal, The New York Times, Bloomberg, Financial Times, The Washington Post, Reuters and The Associated Press. As best as possible we will try to avoid baseless rumors. There is a high probability that many of these potential deals may not materialize and if they do, the terms of the deal may be different from what was initially reported. Please do your own due diligence before buying or selling any securities mentioned on this website. We do not warrant the completeness or accuracy of the content or data provided.